Apellis Pharmaceuticals Inc Cash Flow Reinvestment Rate

Latest as of September 2025: 0.00x

Apellis Pharmaceuticals Inc cash flow reinvestment rate. Apellis Pharmaceuticals Inc (APLS) has a Cash Flow Reinvestment Rate of 0.00x as of September 2025, reinvesting $296.00K (capex $148.00K plus investments $-148.00K) from operating cash flow of $108.47 Million. Explore APLS operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

$296.00K

Capex + Investments

Operating Cash Flow

$108.47 Million

USD

Capital Expenditures

$148.00K

USD

Cash Flow Reinvestment Rate of Apellis Pharmaceuticals Inc (2025–2025)

Cash flow reinvestment rate of Apellis Pharmaceuticals Inc from 2025 to 2025. Historical reinvestment intensity for Apellis Pharmaceuticals Inc across 1 annual periods. Explore APLS capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.

Apellis Pharmaceuticals Inc Cash Flow Reinvestment Rate by Year (2025–2025)

Apellis Pharmaceuticals Inc cash flow reinvestment rate by year from 2025 to 2025. Year-by-year capital reinvestment analysis for Apellis Pharmaceuticals Inc. For the full cash flow conversion analysis, see APLS operating cash flow.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2025	0.01x	$313.00K	$45.33 Million	$313.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow